Navigation Links
Substantial Revenues and Earnings Plus for Gerresheimer
Date:7/14/2010

TDA margin) improved by 2.9 percentage points on the prior year to 20.9% (Adjusted EBITDA margin first six months 19.2%). As a result of the revenues and margin increase, Adjusted EBITDA improved to EUR 56.3m (prior year EUR 47.5m). The profit from operations also improved substantially to EUR 24.8m (prior year: EUR 11.8m). Adjusted earnings per share increased significantly from EUR 0.44 to EUR 0.59.

"We want to remain on our profitable growth path. To this end we will push ahead with the globalization of our business. We therefore want to be an attractive investment for our shareholders and the financial markets. And we take our corporate responsibility towards all stakeholder groups very seriously," says the new CEO Uwe Rohrhoff, outlining his objectives for the company.

Outlook

For the financial year 2010, Gerresheimer AG continues to expect revenues growth in the pharma business, also supported by the emerging markets. The market trend in the more cyclical segments of Cosmetics and Life Science Research (laboratory glassware) is despite first signs of recovery on the other hand more difficult to assess.

On the basis of the good results in the second quarter, Gerresheimer is slightly raising the lower limit of the guidance for the revenues for the financial year 2010. The company assumes revenues, excluding Technical Plastic Systems and at constant exchange rates, to grow by 3% to 4%, compared with 2% to 4% previously. Due to the stronger US Dollar this equivalents a nominal growth rate of 5% to 6% compared with 2% to 4% previously. The forecast for the Adjusted EBITDA margin is raised to 19.5% to 20% (previously around 19.5%). The planned
'/>"/>

SOURCE Gerresheimer AG
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Medivations MDV3100 Demonstrates Substantial PSA Reductions in First Patient Groups Treated in Phase 1-2 Hormone Refractory Prostate Cancer Trial
2. TREANDA Demonstrates Substantial Efficacy in Patients with Relapsed Indolent Non-Hodgkins Lymphoma
3. REMICADE-Treated Patients Experienced Rapid and Substantial Improvement in Psoriasis in Critical Regions of Body
4. NKTR-118 Shows Substantial Oral Bioavailability and Extended Half-Life in Phase 1 Clinical Data Presented at American Pain Society Meeting
5. New International Study Shows Women With Symptomatic Fibroids Delaying Treatment Despite Substantial Burden on Quality of Life
6. Human Genome Sciences Reports Substantial Progress Toward Commercialization and Announces 2009 Goals at JPMorgan Healthcare Conference
7. Study Shows Otamixaban Substantially Reduced Complications of Invasive Management of Acute Coronary Syndromes
8. Sanofi Aventis: Study Shows Otamixaban Substantially Reduced Complications of Invasive Management of Acute Coronary Syndromes
9. Pharma Billionaire Stewart Rahr Provides Substantial Donation to Haiti Charities
10. New Research Shows Over-use of Asthma Rescue Inhalers Substantially Reduced Through Pharmacist-initiated Physician Intervention
11. Delcath Systems Reports Substantial Progress
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... LONDON , May 22, 2015 ... early phase clinical research unit with a worldwide ... respected for its frequent publications in peer reviewed ... and European stakeholders and regulators in discussions about ... results.      (Logo: http://photos.prnewswire.com/prnh/20150522/745125) , ...
(Date:5/21/2015)...  When Ryan Rendino first felt the ... neck, he figured it was a muscle ... from weight lifting. But the ... A series of doctor appointments followed ... Michel Kliot, MD , a Northwestern ...
(Date:5/21/2015)... 2015  CryoLife, Inc. (NYSE: CRY ), a ... cardiac and vascular surgery, announced today that its Board ... the second quarter 2015 of $0.03 per share of ... per share will be paid on June 19, 2015 ... 12, 2015.  The ex-dividend date for the quarterly dividend ...
Breaking Medicine Technology:Northwestern Medicine Surgeons Develop New Approach to Removing Nerve Tumors 2Northwestern Medicine Surgeons Develop New Approach to Removing Nerve Tumors 3Northwestern Medicine Surgeons Develop New Approach to Removing Nerve Tumors 4CryoLife Announces Quarterly Cash Dividend for the Second Quarter 2015 2
... development of DG041 as an,effective anti-platelet that ... June 25, 2007 /PRNewswire-FirstCall/ --,deCODE genetics today ... company's Phase II developmental compound for the,prevention ... Phase IIa and,clinical pharmacology studies presented today ...
... Improving Glycemic Control and,Reducing Diabetic Cardiovascular Complications, ... VeroScience, LLC,in conjunction with its commercialization partner ... its Phase IIIb clinical trial,supporting the overall ... formulation of bromocriptine mesylate) in subjects,with type ...
Cached Medicine Technology:Positive Clinical Results for DG041 Lead Product Development,Highlights at deCODE R&D Event 2Positive Clinical Results for DG041 Lead Product Development,Highlights at deCODE R&D Event 3Positive Clinical Results for DG041 Lead Product Development,Highlights at deCODE R&D Event 4Positive Clinical Results for DG041 Lead Product Development,Highlights at deCODE R&D Event 5Positive Clinical Results for DG041 Lead Product Development,Highlights at deCODE R&D Event 6Phase IIIb Clinical Data Validate the Overall and Cardiovascular,Safety Profile of Cycloset (A Quick Release Formulation of,Bromocriptine Mesylate) in Patients with Type 2 Diabetes 2Phase IIIb Clinical Data Validate the Overall and Cardiovascular,Safety Profile of Cycloset (A Quick Release Formulation of,Bromocriptine Mesylate) in Patients with Type 2 Diabetes 3Phase IIIb Clinical Data Validate the Overall and Cardiovascular,Safety Profile of Cycloset (A Quick Release Formulation of,Bromocriptine Mesylate) in Patients with Type 2 Diabetes 4Phase IIIb Clinical Data Validate the Overall and Cardiovascular,Safety Profile of Cycloset (A Quick Release Formulation of,Bromocriptine Mesylate) in Patients with Type 2 Diabetes 5
(Date:5/24/2015)... Metamora, Michigan (PRWEB) May 24, 2015 ... for concerns about hair loss. Although it is unclear ... that there are environmental factors such as metabolism, nutritional ... contribute. Since they offer a comprehensive approach to evaluating ... and post-menopausal woman, they can help patients find a ...
(Date:5/24/2015)... Scientists with Cardno ChemRisk, a scientific ... compliance issues that may have raised the risk of ... just posted an article on the research. Click ... found airborne asbestos levels well above OSHA safety guidelines ... 2011. , “Asbestos compliance sampling data associated with the ...
(Date:5/24/2015)... Aliso Viejo, CA (PRWEB) May 24, 2015 ... for use in Final Cut Pro X. Utilize ProPin to ... locations in a given scene. , ProPin allows users ... are completely customizable in FCPX. With on-screen controls, video editors ... Studios allows users to pin and mark with absolute ease. , ...
(Date:5/24/2015)... May 24, 2015 ... CEO - The students were ... at the fourth annual A Day ... at Geneva National in Lake Geneva. ...     -Badger High School,         Jonathan Alfonso,         Bridget ...
(Date:5/23/2015)... Washington, D.C. (PRWEB) May 23, 2015 ... demonstration of powers of a youngster's yogic power learned ... by Sri Nithyananda Swami in Bangalore, India. , Yogamaatha, ... of more than 50 high profile professionals attending the ... D.C. by reading fluently -- blindfolded. , In ...
Breaking Medicine News(10 mins):Health News:Women's Excellence Now Treats Menopausal Hair Loss 2Health News:New Analysis Finds Too Many Employers Ignored OSHA Asbestos Guidelines, According to Surviving Mesothelioma 2Health News:Developers at Pixel Film Studios Release ProPin for Final Cut Pro X. 2Health News:Mercy Foundation Honors 16 Students for Making a Difference - Mercy Health System Javon Bea 2Health News:Nine-Year-Old Reads Blindfolded at Business Advocacy Summit 2Health News:Nine-Year-Old Reads Blindfolded at Business Advocacy Summit 3
... , FRIDAY, Feb. 4 (HealthDay News) -- Middle-aged breast cancer ... normally uncommon in women younger than 70, a new study ... that this may be because early menopause caused by breast ... weaken the bones by the time women reach middle age. ...
... be a feminine trait, but for women with peripheral artery ... point to the smaller calf muscles of women as a ... problems walking and climbing stairs sooner and faster than men ... the February 2011 issue of the Journal of the ...
... can prevent 90 percent of genital warts in men when ... the vaccine, according to a new multi-center study led by ... international clinical trial, which also found a nearly 66 percent ... prior exposure to these strains, provides the first reported results ...
... Reporter , THURSDAY, Feb. 3 (HealthDay News) -- While the ... new analysis backs the possibility that cold-like viruses might trigger ... studies, and concluded there is a strong association between enteroviruses ... with diabetes were 10 times more likely to have had ...
... people in employment, men and women who are unemployed suffer ... Why the un-employed should have health problems more often is ... current issue of Deutsches rzteblatt International (Dtsch Arztebl ... findings of the GEDA study. , The GEDA study (Gesundheit ...
... systematic review carried out by a team at the ... studies and concluded that there are benefits to mental ... environment. Their findings are published in the leading research ... February 2011. The research team, supported by the ...
Cached Medicine News:Health News:Breast Cancer Treatment May Lead to Hip Fracture 2Health News:Peripheral artery disease harder on women 2Health News:HPV vaccine works for boys: Study shows first clear benefits 2Health News:Cold Viruses Appear Linked to Type 1 Diabetes 2Health News:Cold Viruses Appear Linked to Type 1 Diabetes 3Health News:Review confirms benefits of outdoor exercise 2Health News:Review confirms benefits of outdoor exercise 3
Round handle colibri tying forceps with 5 mm titanium coated platforms. Length 100 mm....
Round handle McPherson angled tying forceps with 10 mm tips and 5 mm titanium coated platforms. Length 110 mm....
Colibri tying forceps with 5 mm titanium coated platforms. Length 85 mm....
Tennant angled tying forceps with extra delicate smooth jaws, 6 mm tying platform, For 9-0 to 11-0 sutures. Overall length 108 mm....
Medicine Products: